Clinical Hematology International

<Previous Article In Issue
Next Article In Issue>
Volume 2, Issue 1, March 2020, Pages 27 - 31

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia

Authors
Bogdan Popescu, Sheenu Sheela, Julie Thompson, Sophia Grasmeder, Therese Intrater, Christin B. DeStefano, Christopher S. Hourigan*, †, Catherine Lai†
Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Room 10CRC 5-5130, 10 Center Drive, Bethesda, Maryland 20a814-1476, USA
†

Both authors contributed equally.

*Corresponding author. Email: hourigan@nih.gov
Corresponding Author
Christopher S. Hourigan
Received 3 October 2019, Accepted 27 November 2019, Available Online 9 December 2019.
DOI
10.2991/chi.d.191128.001How to use a DOI?
Keywords
Acute myeloid leukemia; Timed sequential chemotherapy; EMA; Chemotherapy; Refractory AML; Relapsed AML; AML
Abstract

Therapy for those with relapsed or refractory acute myeloid leukemia is suboptimal. Studies have suggested that timed sequential salvage combination cytotoxic chemotherapy may be particularly useful for that indication. We report here a series of ten such adult patients treated sequentially at a single center with EMA (cytarabine 500 mg/m2/day as continuous infusion on days 1–3 and days 8–10, mitoxantrone 12 mg/m2/day on days 1–3, and etoposide 200 mg/m2/day as continuous infusion on days 8–10). The overall complete remission rate was 40% (including 3 of 4 of those with relapsed disease), but use of this regimen was associated with prolonged cytopenia and a high rate of infectious adverse events. Even with the availability of modern infectious prophylaxis and therapies, the EMA regimen is likely best reserved for those with relapsed disease treated with curative intent prior to an allogeneic hematopoietic cell transplant.

Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

<Previous Article In Issue
Next Article In Issue>
Journal
Clinical Hematology International
Volume-Issue
2 - 1
Pages
27 - 31
Publication Date
2019/12/09
ISSN (Online)
2590-0048
DOI
10.2991/chi.d.191128.001How to use a DOI?
Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

risenwbib
TY  - JOUR
AU  - Bogdan Popescu
AU  - Sheenu Sheela
AU  - Julie Thompson
AU  - Sophia Grasmeder
AU  - Therese Intrater
AU  - Christin B. DeStefano
AU  - Christopher S. Hourigan
AU  - Catherine Lai
PY  - 2019
DA  - 2019/12/09
TI  - Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
JO  - Clinical Hematology International
SP  - 27
EP  - 31
VL  - 2
IS  - 1
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.191128.001
DO  - 10.2991/chi.d.191128.001
ID  - Popescu2019
ER  -